{"type":"trials","record":{"id":41699,"source_id":"clinicaltrials-gov","external_id":"NCT04679935","title":"Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration","brief_summary":"The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received anti-VEGF (vascular endothelial growth factor) treatment.","overall_status":"Completed","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":52,"countries":["Germany","Switzerland"],"start_date":"2021-07-13","completion_date":"2024-01-31","last_update_date":"2025-09-26","source_url":"https://clinicaltrials.gov/study/NCT04679935","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"FALCON","age_range":"50 Years to 99 Years","comparator":null,"organization":"Novartis","interventions":["Brolucizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Week 40 to Week 52: LS Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — Baseline, We…","Treatment Intervals Before and During the Study — -24 Weeks, Baseline, Week 52","Number of Patients With Prolonged Interval — Baseline, Week 52","Proportion of Patients Who Maintained on q12w Regimen. — Up to week 52","Distribution of Patients at Every 8 Weeks / Every 12 Weeks Intervals - Frequency of Switches in Treatment Intervals Bet…","Mean Change in Best-corrected Visual Acuity — Baseline, Weeks 16 to 28, Week 52","Number of Patients With Best-corrected Visual Acuity Improvements of >= 5, >= 10 and >= 15 Letters — Baseline, up to We…","Number of Patients With Best-corrected Visual Acuity >= 69 Letters — Baseline, up to Week 52","LS Mean Change in Best-corrected Visual Acuity From Baseline at Week 52 — Baseline, Week 52","Change in Central Subfield Thickness From Baseline at Weeks 12, 16, 28 and 52 — Baseline, Weeks 12, 16, 28 and 52","Absence of Intraretinal Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52","Absence of Subretinal Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52","Absence of Sub-retinal Pigment Epithelium Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52","Presence of Active Choroidal Neovascularization Leakage — At Week 52","Overview of TEAEs — Adverse events are reported from first dose of study treatment until end of study treatment plus 30…","Ocular TEAEs in the Study Eye by Primary System Organ Class — Adverse events are reported from first dose of study trea…","Ocular TEAEs in the Study Eye by Preferred Term (at Least 5% in Any Group) — Adverse events are reported from first dos…","Non-ocular TEAEs - Total — Adverse events are reported from first dose of study treatment until end of study treatment…","Ocular TEAEs in the Study Eye of Moderate or Severe Intensity — Adverse events are reported from first dose of study tr…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Age-related Macular Degeneration","Brolucizumab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04679935","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-07-13 to 2024-01-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 99 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.855Z","intervention":["Brolucizumab"],"participants":52,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Week 40 to Week 52: LS Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — Baseline, We…","Treatment Intervals Before and During the Study — -24 Weeks, Baseline, Week 52","Number of Patients With Prolonged Interval — Baseline, Week 52","Proportion of Patients Who Maintained on q12w Regimen. — Up to week 52","Distribution of Patients at Every 8 Weeks / Every 12 Weeks Intervals - Frequency of Switches in Treatment Intervals Bet…","Mean Change in Best-corrected Visual Acuity — Baseline, Weeks 16 to 28, Week 52","Number of Patients With Best-corrected Visual Acuity Improvements of >= 5, >= 10 and >= 15 Letters — Baseline, up to We…","Number of Patients With Best-corrected Visual Acuity >= 69 Letters — Baseline, up to Week 52","LS Mean Change in Best-corrected Visual Acuity From Baseline at Week 52 — Baseline, Week 52","Change in Central Subfield Thickness From Baseline at Weeks 12, 16, 28 and 52 — Baseline, Weeks 12, 16, 28 and 52","Absence of Intraretinal Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52","Absence of Subretinal Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52","Absence of Sub-retinal Pigment Epithelium Fluid in the Central Subfield — Every 4 weeks from baseline up to Week 52","Presence of Active Choroidal Neovascularization Leakage — At Week 52","Overview of TEAEs — Adverse events are reported from first dose of study treatment until end of study treatment plus 30…","Ocular TEAEs in the Study Eye by Primary System Organ Class — Adverse events are reported from first dose of study trea…","Ocular TEAEs in the Study Eye by Preferred Term (at Least 5% in Any Group) — Adverse events are reported from first dos…","Non-ocular TEAEs - Total — Adverse events are reported from first dose of study treatment until end of study treatment…","Ocular TEAEs in the Study Eye of Moderate or Severe Intensity — Adverse events are reported from first dose of study tr…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41699","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}